Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, April 16, 2016

Teva gets patent for invention related to multiple sclerosis drug

April 16, 2016

The company claims that the pharmaceutical composition in the product, related to multiple sclerosis drug Laquinimod, provides superior stabilisation


Israel-based Pharmaceuticals has received approval for a product related to drug Laquinimod. According to reports, is developed by Teva Pharma in collaboration with AB, a Swedish biotechnology company which has focus on neurodegenerative/ inflammatory diseases and cancer.
According to Active Biotech, laquinimod is a compound under development for the treatment of multiple sclerosis and Huntington's disease and the company has an agreement with Teva covering the development and commercialisation of the drug.




                                            ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News 
Providing educational information and resources for those affected by MS
Keep current with Multiple Sclerosis news and information 
To opt-in (sign-up) at our website: click here - thank you
.===================================

No comments: